eleva

Eleva is a biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Our clinical-stage, first-in-class Factor H (CPV-104) program aims to bring the benefits of precision complement modulation to patients suffering from severe kidney disorders, dry AMD and other complement-driven diseases. Beyond CPV-104, our mission is to establish a broad pipeline of unique product candidates that benefit from our moss-based technology and expertise in enabling next-generation medicines.